Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
TRVI Stock | USD 2.88 0.06 2.13% |
Under 58% of all Trevi Therapeutics' traders are looking to take a long position. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that some investors are interested at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
Trevi |
Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough , today announced financial results for the quarter ended June 30, 2024, as well as provided business updates.
Read at finance.yahoo.com
Trevi Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Trevi Therapeutics Fundamental Analysis
We analyze Trevi Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trevi Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trevi Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Trevi Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Trevi Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Trevi Therapeutics stock to make a market-neutral strategy. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics with similar companies.
Peers
Trevi Therapeutics Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
CUE | Cue Biopharma | 11.93 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
PRLD | Prelude Therapeutics | 7.14 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
BCAB | Bioatla | 2.44 | ||||
BOLT | Bolt Biotherapeutics | 1.59 | ||||
RZLT | Rezolute | 1.00 | ||||
SPRO | Spero Therapeutics | 0.88 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
ORIC | Oric Pharmaceuticals | 0.70 | ||||
TARA | Protara Therapeutics | 0.99 | ||||
SEER | Seer | 1.20 | ||||
CHRS | Coherus BioSciences | 3.17 |
Complementary Tools for Trevi Stock analysis
When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |